Aldeyra Therapeutics (NASDAQ:ALDX) Given “Neutral” Rating at HC Wainwright

Aldeyra Therapeutics (NASDAQ:ALDX)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $2.00 target price on the biotechnology company’s stock, down from their prior target price of $10.00. HC Wainwright’s price objective suggests a potential upside of 61.29% from the stock’s current price.

Separately, BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aldeyra Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $1.24 on Wednesday. Aldeyra Therapeutics has a one year low of $1.07 and a one year high of $6.87. The stock has a market capitalization of $74.62 million, a PE ratio of -2.18 and a beta of 0.97. The business’s fifty day moving average is $4.92 and its 200 day moving average is $5.08.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. As a group, sell-side analysts expect that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

Several large investors have recently modified their holdings of ALDX. Caption Management LLC lifted its holdings in Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 132,358 shares during the period. Inspirion Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the 4th quarter worth approximately $52,000. Global Retirement Partners LLC purchased a new position in shares of Aldeyra Therapeutics in the fourth quarter worth approximately $52,000. BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 36.9% in the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after buying an additional 2,859 shares during the last quarter. Finally, CIBC Private Wealth Group LLC bought a new stake in Aldeyra Therapeutics during the third quarter valued at approximately $55,000. Institutional investors own 59.71% of the company’s stock.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Reported short‑interest data appear to be erroneous or incomplete (entries show 0 shares and NaN changes, days‑to‑cover 0.0), so published short‑interest figures may not reflect actual positioning; treat these numbers with caution.
• Negative Sentiment: FDA issued a Complete Response Letter for reproxalap (Aldeyra’s lead dry‑eye therapy), meaning the agency declined approval and identified deficiencies the company must address — the primary catalyst for today’s sell‑off. Aldeyra Therapeutics Receives Complete Response Letter
• Negative Sentiment: Multiple news outlets reported the FDA decline/CRL and highlighted the market reaction (sharp share price declines). Coverage frames this as a major regulatory setback after prior attempts. Reuters: US FDA declines to approve Aldeyra’s drug
• Negative Sentiment: Market commentary emphasizes severity: headlines note a third FDA rejection and large intraday/pre‑market declines, which amplify selling pressure and may prompt forced liquidations or margin selling. MSN: FDA rejects Aldeyra’s dry eye drug for third time
• Negative Sentiment: Heavy bearish options flow: unusual activity shows ~31,566 put contracts traded — a very large increase vs. typical volumes — signaling traders were positioned for or hedging against a sharp drop. This likely exacerbated downside volatility and accelerated selling.
• Negative Sentiment: Shareholder litigation/insider scrutiny: multiple law firms (Block & Leviton; Johnson Fistel) have announced investigations into Aldeyra’s disclosures and executive conduct, which can increase legal overhang, distract management, and deter some buyers. Seeking Alpha: Aldeyra plunges as FDA rejects dry eye disease therapy
• Negative Sentiment: Secondary coverage and local reporting of investor alerts and class‑action solicitations further amplify negative sentiment and could prolong depressed trading until clarity on an appeals/resubmission path or cash/dilution plan emerges. Caledonian Record: Aldeyra investigated for securities fraud

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.